Tianyuan Medical (00557.HK): Hengqin Han Yue Mei and Shanghai Rifu plan to increase capital to Shanghai Rifu.

The Zhijun Finance and Economics APP News, Tianyuan Medical (00557.HK) announced that on July 21, 2025, Hengqin Hanyue Mei (an indirect wholly-owned subsidiary of the Company) and Shanghai Rifubu (an indirect non-wholly-owned subsidiary of the Company) entered into a capital increase agreement with Shanghai Huaman. Hengqin Hanyue Mei will increase capital to Shanghai Rifubu by RMB 155.152 million (approximately HKD 169.116 million), by converting the RMB 155.152 million (approximately HKD 169.116 million) owed by Shanghai Rifubu to Hengqin Hanyue Mei into capital; and Shanghai Huaman will increase capital to Shanghai Rifubu by RMB 100 million (approximately HKD 109 million) in cash, the two increases will be based on the corresponding shareholding ratios of Hengqin Hanyue Mei and Shanghai Huaman in Shanghai Rifubu.